Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$52.06 - $61.27 $5.26 Million - $6.19 Million
-101,100 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$44.23 - $57.5 $3.47 Million - $4.51 Million
-78,500 Reduced 43.71%
101,100 $5.22 Million
Q4 2020

Feb 16, 2021

SELL
$33.21 - $46.54 $9.9 Million - $13.9 Million
-298,252 Reduced 62.42%
179,600 $7.78 Million
Q3 2020

Nov 16, 2020

BUY
$33.87 - $55.93 $4.9 Million - $8.09 Million
144,593 Added 43.39%
477,852 $16.7 Million
Q2 2020

Aug 14, 2020

BUY
$34.45 - $53.48 $6.98 Million - $10.8 Million
202,645 Added 155.15%
333,259 $17.8 Million
Q1 2020

May 15, 2020

BUY
$31.52 - $53.81 $4.12 Million - $7.03 Million
130,614 New
130,614 $4.63 Million
Q3 2019

Nov 15, 2019

SELL
$32.4 - $49.58 $218,797 - $334,813
-6,753 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$46.17 - $68.1 $4.88 Million - $7.2 Million
-105,705 Reduced 94.0%
6,753 $337,000
Q1 2019

May 15, 2019

SELL
$45.92 - $67.67 $1.95 Million - $2.88 Million
-42,542 Reduced 27.45%
112,458 $7.58 Million
Q4 2018

Feb 14, 2019

SELL
$42.73 - $76.53 $884,510 - $1.58 Million
-20,700 Reduced 11.78%
155,000 $7.15 Million
Q3 2018

Nov 14, 2018

BUY
$71.67 - $91.95 $1.47 Million - $1.88 Million
20,500 Added 13.21%
175,700 $13.6 Million
Q2 2018

Aug 14, 2018

SELL
$73.22 - $99.55 $18.4 Million - $25 Million
-250,890 Reduced 61.78%
155,200 $13.1 Million
Q1 2018

May 15, 2018

BUY
$59.83 - $86.53 $18.8 Million - $27.2 Million
314,590 Added 343.81%
406,090 $33.2 Million
Q4 2017

Feb 14, 2018

SELL
$52.12 - $72.33 $1.99 Million - $2.76 Million
-38,140 Reduced 29.42%
91,500 $5.23 Million
Q3 2017

Nov 14, 2017

BUY
$54.89 - $67.12 $7.12 Million - $8.7 Million
129,640
129,640 $8.65 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $2.99B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.